AER 1613835 is a spontaneous case received on 27/Jul/2015,  from an other health care professional via canadian
health authority (reference number: E2B294246) and concerns a patient of unknown demographics who 
experienced apathy, aphasia, executive dysfunction, fatigue, jc virus test positive, neurological decompensation, 
progressive multifocal leukoencephalopathy, white matter lesion whilst being treated with mycophenolate mofetil 
(Mycophenolate Mofetil), belimumab (Belimumab), hydroxychloroquine (Hydroxychloroquine), prednisone 
(Prednisone).
No medical history, concurrent conditions, concomitant medications and past drugs were reported.
On an unspecified date, patient started therapy with mycophenolate mofetil (1500 mg, twice a day, route not 
reported) for systemic lupus erythematosus, belimumab (dosing regimen not reported) for unknown indication, 
hydroxychloroquine (dosing regimen not reported) for systemic lupus erythematosus, prednisone (10 mg, route and
frequency not reported) for unknown indication. On an unspecified date, patient developed apathy, aphasia, 
executive dysfunction, fatigue, jc virus test positive, neurological decompensation, progressive multifocal 
leukoencephalopathy, white matter lesion.
At the time of the report, apathy, aphasia, executive dysfunction, fatigue, jc virus test positive, neurological 
decompensation, progressive multifocal leukoencephalopathy, white matter lesion were persisting. It was not 
known if therapy with mycophenolate mofetil, belimumab, hydroxychloroquine and prednisone were ongoing.
The reporter did not assess causal relationship for events apathy, aphasia, executive dysfunction, fatigue, jc virus 
test positive, neurological decompensation, progressive multifocal leukoencephalopathy, white matter lesion with 
mycophenolate mofetil, belimumab, hydroxychloroquine and prednisone. 
No further information was provided.